Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis

University of Utah

Overview

RATIONALE: Exisulind may be effective in preventing the development and growth of polyps in patients who have familial adenomatous polyposis. PURPOSE: Randomized phase II/III trial to determine the effectiveness of exisulind in preventing the development and growth of polyps in patients who have familial adenomatous polyposis.

OBJECTIVES: * Determine the ability of exisulind to inhibit growth and development of duodenal adenomas in patients with familial adenomatous polyposis. * Determine the effect on apoptosis in polyp vs mucosal tissue in these patients when treated with this drug. OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to one of two treatment arms. * Arm I: Patients receive oral exisulind 4 times daily. * Arm II: Patients receive oral placebo 4 times daily. Treatment continues for 1 year. PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Conditions

Colorectal Cancer Small Intestine Cancer

Interventions

exisulindDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * One of the following diagnosis: * Diagnosis of familial adenomatous polyposis * Prior total or subtotal colectomy * Attenuated adenomatous polyposis coli * May have colon intact * 10-40 duodenal polyps from second portion to 10 cm distal to papilla of Vater PATIENT CHARACTERISTICS: Age: * 18 to 80 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Hemoglobin at least 10 g/dL * Platelet count at least 100,000/mm\^3 * No active hematologic disease Hepatic: * AST and ALT less than 1.5 times upper limit of normal (ULN) * Alkaline phosphatase less than 1.5 times ULN * No active hepatic disease Renal: * Creatinine less than 1.5 mg/dL * No active renal disease Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No active peptic ulcer disease * No serious underlying medical or psychiatric illness that would preclude completion of the study or limit survival * No prisoners or institutionalized patients * No known allergy to sulindac or related compounds * No active internal malignancy within the past 5 years * No alcohol or drug abuse within the past 5 years PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * See Disease Characteristics Other: * No prior non-steroidal anti-inflammatory drugs (NSAIDs) or salicylates more than 10 days a month for the past 3 months * No concurrent NSAIDs (e.g., mesalamine, olsalazine, azodisalicylate, salsalate, sulfasalazine) * Aspirin for cardiac reasons allowed (81 mg/day or 325 mg twice/week)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.